NEWSROUND
Selected Reports by Janet Fricker Download full article
GIST
The treatment of gastrointestinal stromal tumours (GIST)
Better understanding of the different mutations that drive GIST is leading to new paradigms of tailored treatment that break many norms of chemotherapy, especially in management of progression. Download full article
GIST adjuvant therapy – some answers and more questions
Imatinib is known to be effective in the first-line treatment of metastatic gastrointestinal stromal tumours. A randomised, placebo-controlled trial has now shown that imatinib is safe and improves recurrence-free survival when used as adjuvant therapy [more]
Europe’s rare cancer community calls for a more radical approach
The genomic era offers enormous potential for patients with rare cancers, but progress is being held back by structures that separate research from care, regulatory practices that penalise small patient populations, and rules that restrict [more]
When is it OK to randomise cancer patients to placebo?
No-one wants to see progress in cancer research more than the patients themselves. But how do we deal with potential conflicts of interest when testing new drugs involves giving placebos to people dying of cancer? [more]
We don’t have to be a year behind
Late last year, US patients with advanced renal cell cancer gained access to an oral multi-kinase inhibitor, Nexavar (sorafinib) the first new drug approved for this disease in the last 10 years. Manufacturer Bayer [more]